|
Volumn 82, Issue 2, 1992, Pages 317-323
|
Recombinant human granulocyte‐macrophage colony‐stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a British National Lymphoma Investigation double‐blind, placebo‐controlled trial
a a a a b b c c d d e f g h i j j k |
Author keywords
[No Author keywords available]
|
Indexed keywords
CARMUSTINE;
CYTARABINE;
ETOPOSIDE;
MELPHALAN;
PLACEBO;
RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;
ADULT;
ARTICLE;
AUTOLOGOUS BONE MARROW TRANSPLANTATION;
CLINICAL TRIAL;
CONTROLLED STUDY;
DOUBLE BLIND PROCEDURE;
DRUG TOXICITY;
FEMALE;
HUMAN;
LYMPHOMA;
MAJOR CLINICAL STUDY;
MALE;
NEUTROPENIA;
PRIORITY JOURNAL;
THROMBOCYTE;
ADOLESCENT;
ADULT;
AGED;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BONE MARROW TRANSPLANTATION;
COMBINED MODALITY THERAPY;
DOUBLE-BLIND METHOD;
GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR;
HUMAN;
LEUKOCYTE COUNT;
LYMPHOMA;
MIDDLE AGE;
NEUTROPHILS;
PLATELET COUNT;
PROSPECTIVE STUDIES;
RECOMBINANT PROTEINS;
SUPPORT, NON-U.S. GOV'T;
TIME FACTORS;
|
EID: 0026646258
PISSN: 00071048
EISSN: 13652141
Source Type: Journal
DOI: 10.1111/j.1365-2141.1992.tb06424.x Document Type: Article |
Times cited : (54)
|
References (9)
|